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ABSTRACT: As lipids are assigned a plethora of biological
functions, it is evident that dysregulated lipid metabolism
signiﬁes a key element in many pathological conditions. With
this rationale, this study presents a validated lipidomics
platform to map the fecal lipidome, which integrates unique
information about host−gut microbiome interactions, gastro-
intestinal functionality, and dietary patterns. This particular
method accomplished coverage across all eight lipid categories:
fatty acyls, glycerolipids, phosphoglycerolipids, polyketides,
prenols, saccharolipids, sphingolipids, and sterols. Generic
extraction of freeze-dried feces was achieved by solid−liquid
extraction using methanol and methyl tert-butyl ether. Extracted components were separated by liquid chromatography, whereby
the selected ethylene-bridged hybrid phenyl ultra-high-performance liquid chromatography stationary phase allowed fast
separation of both individual lipid species and categories. Detection was achieved by high-resolution full-scan Q-Exactive
Orbitrap mass spectrometry and covered a broad m/z scan range (67−2300 Da). Method validation was performed in a targeted
fashion to evaluate the analytical performance across all lipid categories, revealing excellent linearity (R2 ≥ 0.9921), acceptable
repeatability (coeﬃcients of variance ≤15.6%), and stable recovery (coeﬃcients of variance ≤11.9%). Method suitability for
untargeted ﬁngerprinting was veriﬁed, demonstrating adequate linearity (R2 ≥ 0.90) for 75.3% and acceptable repeatability
(coeﬃcients of variance ≤30%) for 84.5% of about 9000 endogenous fecal compounds. Eventually, the potential of fecal
lipidomics was exempliﬁed within a clinical context of type 2 diabetes, thereby revealing signiﬁcant perturbations [orthogonal
partial least-squares discriminant analysis Q2(Y) of 0.728] in the fecal lipidome between participants with normal blood glucose
levels (n = 26) and those with type 2 diabetes (n = 17).
The chemical complexity among lipids was a majorincentive for the LIPID MAPS consortium to establish a
classiﬁcation system based on eight lipid categories: fatty acyls
(FA), glycerolipids (GL), glycerophospholipids (GP), poly-
ketides (PK), prenol lipids (PL), saccharolipids (SL),
sphingolipids (SP), and sterol lipids (ST). Each category is
characterized by a profound hierarchy of classes and subclasses,
by which a total of about 40 000 biologically relevant species
have been incorporated to date.1 Following this complexity,
lipids are involved in a plethora of biological processes,
including energy homeostasis, immune response, membrane
architecture, enzyme activity, inﬂammation, cellular signaling,
and transduction of cellular events.2−5 Evidently, a dysregulated
lipid metabolism has been implicated in a variety of
pathological conditions such as diabetes mellitus, obesity,
Alzheimer’s disease, schizophrenia, cancer, atherosclerosis, and
multiple sclerosis.4,6−8 In-depth assessment of the biological
relevance of lipid alterations in biological systems may thus
yield valuable insights on metabolic homeostasis in relation to
human health and disease.9
On this basis, the lipidomics domain has recently emerged,
whereby the aim is to map the complete assortment of
molecular lipid species together with associated metabolic
ﬂuxes.10 Although any biological matrix can be selected, the
most frequently used specimens to explore lipid alterations are
serum,11,12 plasma,13,14 and urine.15,16 Feces also represents an
interesting choice because of the unique link with gastro-
intestinal functionality, encompassing gut integrity and
digestive and absorptive processes.17 Moreover, this biological
matrix strongly reﬂects dietary intake and captures the tight
Received: September 3, 2017
Accepted: October 20, 2017
Published: October 20, 2017
Article
pubs.acs.org/ac
© 2017 American Chemical Society 12502 DOI: 10.1021/acs.analchem.7b03606
Anal. Chem. 2017, 89, 12502−12510
Cite This: Anal. Chem. 2017, 89, 12502-12510
interactions between the host and gut-residing microbiota, for
which a causal role in various pathologies has been
evidenced.18−20 For these reasons and because of the
noninvasive nature of sample collection, the fecal metabolome
has recently been studied in colon cancer, ulcerative colitis,
irritable bowel syndrome, and autism.21−23 However, these
studies tend to focus only on the polar subfraction of the
metabolome, typically comprising small polar molecules such as
amino acids, carbohydrates, bile acids, organic acids, etc.
To date, the 2013 study of Gregory et al.17 is the sole one to
report on fecal lipidomics, whereby the presented analytical
methodology was demonstrated to cover six out of eight lipid
categories and characterized up to 300 lipophilic species in fecal
matter from premature infants. Lipid proﬁles were established
by high-performance liquid chromatography (HPLC) coupled
to high-resolution mass spectrometry (MS), which has indeed
emerged as the most expedient strategy to perform global
quantitative measurements of lipids in complex mixtures.
Nevertheless, implementation of LC in lipidomics is not
straightforward due to the wide polarity range across the lipid
population, which hampers the eﬃcient separation of lipid
categories and molecular species therein. In this regard,
complex LC methodologies with extended elution times,
ternary or quaternary gradient programs, or the use of two-
dimensional (2D) chromatography have been proposed.24 Also
at the level of extraction, the heterogeneity of the lipidome in
terms of polarity and concentration range brings about
diﬃculties in achieving adequate extraction of lipids across all
categories. For example, in order to align with the varied lipid
properties, the workﬂow of Gregory et al.17 applied two
separate and complementary extraction chemistries, dichloro-
methane and methyl tert-butyl ether/hexaﬂuoro-2-propanol.
The complexity of the lipidome thus is associated with some
major analytical challenges but is also considered one of the
reasons that lipidomics connotes a promising research ﬁeld
with lots of unexploited potential.
The objective of this study was to establish an analytical
methodology for robust ﬁngerprinting of the fecal lipidome.
The speciﬁc intentions of this work were to (i) develop a
simple extraction protocol based on a single extraction
chemistry, (ii) optimize a short ultra-high-performance liquid
chromatography (UHPLC) strategy to achieve separation of
lipid categories as well as individual lipid species within the
categories, (iii) establish full-scan detection on a hybrid system
that also oﬀers possibilities for selective fragmentation, and (iv)
achieve coverage across all eight lipid categories. In addition,
the methodology was validated in a targeted and untargeted
fashion to assess the method of being ﬁt-for-purpose for all
eight lipid categories and in an omics context, respectively.
Finally, lipidomic ﬁngerprinting of fecal samples from type 2
diabetes patients and healthy controls was performed to
demonstrate the discriminative power of fecal lipidomics in
health and disease. Type 2 diabetes mellitus was particularly
interesting due to the associated dyslipidemia,25 acknowledged
role of microbiota,26 and strong impact of dietary pattern,27
presumed to be integrated by the fecal lipidome.
■ MATERIALS AND METHODS
Reagents and Chemicals. Analytical reference standards
were obtained from diverse suppliers (Table S1) and carefully
chosen in order to attain adequate representation of the LIPID
MAPS1 classiﬁcation structure. Hereby, as a minimum
condition, at least one reference standard for each of the
eight main lipid categories was selected. Internal standards were
obtained for most of these categories and included deuterium-
labeled and non-naturally-occurring compounds (Table S2).
Being aware of the fact that several classes or subclasses may
not be covered by the constructed database of analytical
standards, we considered it critically important to implement a
truly untargeted evaluation approach during both method
development and validation to ensure holistic coverage.
Stock solutions were made at a concentration of 1 mg·mL−1,
whereby appropriate solvents were selected on the basis of the
compounds’ polarity index (Tables S1 and S2). These solutions
and dilutions thereof were stored in amber glass bottles at −20
°C. Solvents were of analytical grade for extraction purposes
and LC/MS grade for UHPLC/MS applications and were
purchased from VWR International (Merck) and Thermo
Fisher Scientiﬁc. Ultrapure water (0.055 μS·cm−1) was obtained
via a puriﬁed water system (VWR International, Merck).
Biological Samples. For development and validation of the
method, pools of lyophilized fecal material were used,
containing equal shares from at least six healthy adults. These
persons were not subjected to any antibiotic treatment during
the 3 months before sample donation, and no dietary
restrictions were imposed. Lyophilization of fresh samples
was performed for approximately 48 h, leading to the removal
of 69.3% ± 3.8% water. Lyophilized material was ground,
sieved, and stored at −80 °C until use.
Optimization of Lipid Extraction. The extraction
protocol was optimized on the basis of a fractional factorial
screening design (Modde 5.0, Umetrics) by which six factors
were assessed: amount of feces (design values of 100 and 250
mg dry weight), volume extraction solvent (5% and 10% w/v),
vortex time (20 and 60 s), incubation time (0 and 60 min, at 4
°C and 0 rpm), type of extraction solvent [methanol/methyl
tert-butyl ether (1/3 v/v), methanol/dichloromethane (1/2 v/
v), and methanol/chloroform (1/2 v/v)], and incorporation of
a rotation step (yes or no). This rendered a D-optimal design
with 27 experiments (24 design runs and three center points),
whereby the main eﬀect of each variable was statistically
evaluated (Modde 5.0, Umetrics) based on the metabolome
coverage and intensity of 53 targeted lipid species, speciﬁcally
representing all eight lipid categories.
Following the screening phase, response surface modeling
(RSM) was applied to optimize signiﬁcant quantitative factors,
that is, amount of starting material (RSM values of 100, 200,
and 300 mg), volume of extraction solvent (5.0%, 1.7%, and
10% w/v), vortex time (20, 40, and 60 s), and methanol/
methyl tert-butyl ether solvent ratio (1/3, 1/6, and 1/9 v/v).
Modeling was eﬀectuated by considering the absolute
metabolome coverage and intensity of the 53 selected lipid
species. Along with the modeling-based optimizations, the
following factors were assessed by full factorial designs with at
least three technical replicates: addition of an antioxidant to the
extraction solvents [0.01% (w/v) butylhydroxytoluene,
BHT],28 acidiﬁcation of the water phase [5% (w/v) trichloro-
acetic acid],9 shaking (200 rpm) instead of rotation, number of
solid−liquid extraction cycles (one or two), and use of
alternative nonpolar solvents (ethyl acetate and diethyl
ether).29 The ﬁnal step concerned optimization of the extract
dilution factor.
Final Extraction Protocol. The ﬁnal protocol for generic
extraction of lipids started with the addition of 1200 μL of
methanol containing 0.01% BHT (w/v) to 200 ± 0.50 mg of
lyophilized and homogenized fecal material. After this mixture
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was vortexed for 30 s, a total volume of 5.4 mL of methyl tert-
butyl ether with 0.01% BHT (w/v) was added, after which a
new vortex step of 30 s was applied. Subsequently, the sample
was shaken for 20 min at 200 rpm at 20 °C in an incubator
(New Brunswick Innova 42, Eppendorf). Thereafter, 3 mL of
ultrapure water with 2.5% trichloroacetic acid (w/v) was added
to induce phase separation, which was enforced by
centrifugation for 5 min at 3000 rpm at 20 °C. Next, 1 mL
of the upper layer, consisting of methyl tert-butyl ether, was
collected and evaporated to dryness at 30 °C under a gentle
stream of nitrogen. The residue was sequentially suspended in
250 μL of chloroform and 650 μL of methanol, after which a
50-μL subfraction was transferred to an amber glass vial and
diluted 1/2 by the addition of 50 μL of methanol internal
standard mixture (internal standard concentrations between 2
and 100 ng·μL−1). An aliquot (5 μL) of sample was injected
into the chromatographic system.
Liquid Chromatographic Separation and Mass Spec-
trometric Detection. Liquid chromatography was achieved
on a Dionex Ultimate 3000 XRS UHPLC system (Thermo
Fisher Scientiﬁc), which was equipped with an Acquity
ethylene-bridged hybrid (BEH) phenyl column (2.1 × 150
mm, 1.7 μm). Hereby, a binary solvent system consisting of
ultrapure water (solvent A) and methanol (solvent B), both
acidiﬁed with ammonium acetate (3.5 mM), was used to
establish a gradient elution program. The following proportions
(v/v) of solvent B were used: 0−1 min at 75%, 1−2 min from
75% to 90%, 2−6 min from 90% to 98%, 6−15 min from 98%
to 100%, and 15−17 min at 100%, followed by 3 min of
equilibration at initial conditions. A constant ﬂow rate of 300
μL·min−1 and a column oven temperature of 40 °C were set.
MS analysis was carried out by high-resolution hybrid
quadrupole Q-Exactive Orbitrap MS (Thermo Fisher Scien-
tiﬁc), preceded by heated electrospray ionization (HESI-II) that
operated in polarity switching mode. Analysis was realized
through full-scan events with following instrumental settings;
sheath gas ﬂow of 40 arbitrary units (au), auxiliary gas ﬂow of
10 au, sweep gas ﬂow of 2 au, heater and capillary temperature
both 325 °C, S-lens RF level of 80 au, and spray voltage for
positive and negative ionization 3.5 and 3.0 kV, respectively.
Furthermore, mass resolution of 70 000 full width at half-
maximum (fwhm; 1 Hz), AGC (automatic gain control) setting
of 2 × 105 ions, and maximum injection time of 50 ms were
selected. The m/z scan range was set from 67 to 1000 Da for
both positive and negative ionization modes. After 4.5 min,
additional scan events with a scan range of 1000−2300 Da were
initiated to cover high-mass lipid species.
Precautions To Avoid Contamination during Analysis.
To avoid the introduction of extraneous lipophilic substances
from sources other than the fecal material, various precau-
tionary measures were taken. First, all recipient vessels used
during extraction consisted of Teﬂon (40 mL, VWR Interna-
tional, Germany), which is known to show high temperature
and chemical resistance. These tubes were extensively cleaned
by two cycles of chloroform and acetone, after which they were
dried at 75 °C. Second, all other accessories (tips, beaker, pipet,
Pasteur, Erlenmeyer) were made of glass and also cleaned by
the protocol described. Third, a Hypersil Gold column (50 ×
2.1 mm, 1.9 μm) (Thermo Scientiﬁc) was installed between the
LC pump and injector valve. This column served as a delay
column with the purpose of retarding any lipophilic compounds
originating from the solvent system.30
Method Validation. In accord with the guidelines of Naz et
al.,31 the method’s analytical performance was thoroughly
assessed in an untargeted and targeted fashion. With respect to
the latter, one representative per lipid category was considered:
12-tridecanoic acid (FA), 1-monoolein (GL), coenzyme Q10
(PR), chrysophanol (PK), 1-palmitoyl-2-oleoyl-sn-glycero-3-
phospho-L-serine (GP), lithocholic acid (ST), lactonic
sophorolipid (SL), and N-oleoyl-D-erythro-sphingosine (SP).
Selection of these particular compounds was based on their
endogenous absence or low abundance in the fecal material,
simplifying any fortiﬁcation experiments.
Linearity was assessed per lipid category by considering an
eight-point calibration curve for each of the lipid target
compounds. Associated concentration series were set up in the
fecal material prior to extraction (Table 2). In case that the lipid
target compound was endogenously absent in the fecal material,
the lowest concentration was chosen so as to reach a minimum
integrated peak area of about 1 000 000 au, whereas the upper
level was 16 times higher. Usage of the peak area as a decision
criterion instead of the signal-to noise ratio (S/N) was related
to the features of the HRMS instrument, where S/N is often
inﬁnite. For those lipids that were endogenously present,
selection of the upper calibration point was of course most
important, whereby it was opted to add at least 2 times the
endogenously expected amount of the compound to the fecal
material. Linearity was also evaluated in an untargeted way
through a nine-point dilution series (adjusted dilutions of fecal
extract), covering factors from 1/50 to 8/1. Linearity
performance was assessed each time on the basis of the
determination coeﬃcient. Recovery was evaluated in a targeted
fashion only, whereby adjusted amounts of analytical standards
were added to either fecal material or extract. The ratio of the
recovered amounts in both cases was the measure for recovery.
Hereby, three levels were considered with six replicates per
level (Table 2). Repeatability was assessed by analysis of nine
fecal samples by the same analyst under repeatable conditions,
whereas an additional set of nine samples was analyzed by
another analyst on a diﬀerent day to allow evaluation of the
intralaboratory reproducibility. Enriching these samples with
some speciﬁc target compounds prior to extraction enabled the
targeted assessment of precision across all categories (Table 2).
In addition, the short-term instrumental precision was
investigated by sequentially injecting three fecal extracts 10
times.
Data Analysis. XCalibur 3.0 software (Thermo Fisher) was
used for targeted processing of full-scan data, including
identiﬁcation and quantiﬁcation of lipid target compounds.
Identiﬁcation of a compound was realized by use of the m/z
value of the molecular ion (mass deviation ≤3 ppm), the C
isotope pattern (13C/12C isotope ratio that is compliant with
CD 2002/657/EC guidelines),38 and the retention time relative
to that of an internal standard (deviation ≤2.5%), all being
determined from the corresponding analytical standard. Sieve
2.2 (Thermo Fisher Scientiﬁc) was applied for untargeted data
interpretation, characterizing detected ions in terms of m/z
value, retention time, and peak intensity. Parameters for
automated peak alignment, noise removal, peak extraction,
and deconvolution are presented in Table S3. This work did
not intend to identify the individual species from the lipidomic
ﬁngerprints, with the exception of those that matched an
analytical standard. Multivariate data analysis was performed
with SIMCA 14.1 (Umetrics).
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Fecal Lipidomics in a Clinical Context. The lipidomics
methodology was employed to assess any perturbations in the
fecal lipidome in relation to blood glycemic state. Hereby,
individuals without (n = 26) and with type 2 diabetes (n = 17)
were engaged to participate and deliver one fecal sample.
Classiﬁcation of individuals was based on the glycated
hemoglobin (Hb A1c) level, measured in venous whole blood
by HPLC (Tosoh). Hereby, a Hb A1c level of 60 mmol·mol−1
was taken as the criterion for type 2 diabetes. This particular
study was approved by the UZ Ghent Ethical Committee (EC
2016/0673). Other factors such as age, weight, body mass
index, gender, and diet were veriﬁed as nonconfounding, as the
factor-speciﬁc orthogonal partial least-squares discriminant
analysis (OPLS-DA) models were not validable.
■ RESULTS AND DISCUSSION
Ultra-High-Performance Liquid Chromatography Op-
timization. Although direct infusion ESI-based shotgun
lipidomics represents a powerful approach for rapid analysis
of lipids, there are some serious limitations in terms of ion
suppression and separation of isobaric and isomeric com-
pounds. These limitations may be addressed by liquid
chromatography, which oﬀers high resolution and better
reproducibility.2,6 In the case of reversed-phase LC, separation
mainly depends on the characteristics of the fatty acid chain,
which allows one to distinguish between species within a lipid
class or subclass. Conversely, normal-phase chromatography
relies on the physical properties of the lipid headgroup and
generally achieves separation between lipid (sub)classes.3 Only
recently, it was accomplished by Olsson et al.32 to combine
both separation principles, by using 5-μm particles of phenyl-
coated silica (i.e., Reprosil-Pur 120 phenyl). Accordingly, in this
study, an Acquity BEH phenyl C18 column (2.1 × 150 mm, 1.7
μm) was tested and proven to show an analogous separation
performance while being compatible with UHPLC. Indeed, as
exempliﬁed by the elution proﬁle of some saturated and
unsaturated fatty acids (Figure 1), interaction with the
stationary phase appeared to be a function of the length of
the carbon chain and its degree of saturation. Chromatographic
separation of individual lipid species was thus dependent on the
Figure 1. Interaction between fatty acids and the C18 BEH phenyl stationary phase with separation according to carbon chain length (left) and
number of unsaturated bounds (right).
Figure 2. Fecal lipidomic ﬁngerprint including both positively and negatively ionized constituents (total number of 13 153 ions). In total, 127
reference standards were located, demonstrating class-related time zones.
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arrangement of the fatty acid groups, providing opportunities
for retention time prediction.32
In addition, the use of retention time windows (Figure 2)
may also assist in structural elucidation of unknowns, as
information on the polar headgroup and thus lipid category
could be acquired as well. In conclusion, the BEH phenyl
stationary phase was found highly suitable for high-throughput
lipidomics chromatography.
Mobile-phase composition was optimized by testing various
organic solvents (methanol, acetonitrile, and 2-propanol) in
combination with adapted complements of ultrapure water.
Although the speed of elution could be increased for various
lipids by using 2-propanol, this solvent was disadvantageous for
the chromatographic peak shape of several compounds, in
particular FA (average As of 1.26 ± 0.13). In this respect,
methanol and acetonitrile performed much better (average As
≤ 1.12 ± 0.14 for FA and ≤1.14 ± 0.19 for all lipids), whereby
better sensitivity was generally achieved in case of methanol.
Indeed, when methanol was used instead of acetonitrile, peak
intensities were increased by a factor between 1.5 (for FA) and
15 (for prenol lipids). Additionally, various mobile-phase
additives were evaluated: ammonium acetate, ammonium
formate, acetic acid, formic acid, and combinations thereof.
The addition of 3.5 mM ammonium acetate was most suitable,
as the sensitivity was signiﬁcantly improved for almost all lipid
species, resulting in an increase in class-based average sensitivity
by a factor of about 4.
Eventually, a column oven temperature of 40 °C was set, as
higher temperatures were accompanied by a signiﬁcant
degradation of numerous lipid species. In cases where
temperatures were ≥45 °C, a strong reduction in peak intensity
(28.1% on average, ranging between 5.4% and 79.6%) was
noted for compounds from all lipid classes (with the exception
of FA, which were found to be rather inert up to 50 °C).
However, 35 °C was observed to result in decreased signal
intensities (on average 1.8−17.6%) for most lipid classes with
the exception of ST and PR (increased by 1.7% and 7.1%,
respectively). Moreover, lower temperatures were also not
feasible, as these caused the column back pressure to exceed its
maximum limit (mainly due to combination with the delay
column). Also for this reason, the mobile-phase ﬂow rate was
kept at 300 μL·min−1.
Optimization of Heated Electrospray Ionization and
Full-Scan Orbitrap Mass Spectrometry. Prior to determin-
ing the optimal MS conditions, lipid analytical and internal
standards were directly infused into the HESI source (50 ng·
min−1) or separately injected (up to 100 ng) to determine the
most abundant adducts and their accurate masses (m/z values).
Hereby, [M − H]−, [M + H]+, and [M + NH4]+ adducts were
most common. In this context, it should be noted that the most
intense signal for SL Kdo2-lipid A was obtained for the double-
charged molecular ion in negative ionization mode. From this,
it may be expected that other SL species, also characterized by
high molecular weights, may be retrieved as double-charged
ions as well. Another ﬁnding concerned the analysis of
cholesteryl linoleate; it was found that this particular cholesterol
ester releases cholesterol through in-source fragmentation, as
observed upon analysis of the analytical standard (≥98%
purity). As the associated cleavage process takes place after LC
separation, this process does not interfere with the semi-
quantitation of cholesterol (directly originating from the fecal
extract), which elutes earlier than cholesteryl linoleate (Table
S1). Optimization of parameters was mainly based on the peak
intensity of the individual lipids as well as the overall sensitivity
per lipid class.
Full-scan MS parameters were optimized for fecal extracts
and mainly concerned the mass resolution and AGC target.
Evaluation of resolution was based on the achieved mass
accuracies and number of data points across the chromato-
graphic peaks. Increased mass resolution is accompanied by
improved mass accuracy and selectivity, due to superior
exclusion of isobaric matrix interferences. However, this also
implies prolonged scan times with fewer data points across a
peak, which can be detrimental for repeatability and sensitivity.
Accordingly, a mass resolution of 70 000 fwhm was found to
deliver good quantitative performance, as low mass deviations
were noted (<3 ppm) while the number of data points was still
satisfactory (≥7).33 The optimal AGC target was 2 × 105 ions,
as this was associated with the highest S/N ratios and low mass
deviations (<3 ppm).
Optimization of Extraction. The extraction procedure was
optimized by a D-optimal design (G-eﬃciency of 99.9%),
whereby the signiﬁcance of each factor was evaluated on the
basis of metabolome coverage and absolute peak areas of 53
lipid species, representing all eight lipid categories. The results
for this screening phase are summarized in Table 1.
The type of extraction solvent was ascribed the highest
impact (variable importance in the project of 1.30). Usage of
methanol/methyl tert-butyl ether rendered the highest signal
intensities for lipid species from FA, GP, SP, ST, and PK (Table
S4). Moreover, this extraction solvent was accompanied by
higher metabolome coverage. This is in accordance with
Matyash et al.,34 who found similar or better recoveries for
most lipid categories when using methyl tert-butyl ether instead
of applying the Folch or the Bligh and Dyer method. Here, the
low density of methyl tert-butyl ether simpliﬁes collection of the
lipid-containing phase (which is the upper layer during liquid-
phase extraction), allowing easy removal of nonextractable
interferences such as denatured proteins by centrifugation.9
The incorporation of methanol intended to disrupt the strong
interactions between lipids and cell biopolymers such as
proteins and polysaccharides,9 presumed to manifest during the
incubation period, as this factor aﬀected the recovery of polar
lipids, mainly short-chain FA (Table S4). Therefore, to
Table 1. Impact of Investigated Factors on Extractiona
no. of lipids aﬀected
factor positively negatively
metabolome
coverage
volume extraction solvent (upper
value)
4 12 no eﬀect
amount of feces (upper value) 12 4 no eﬀect
vortex time (upper value) 2 1 no eﬀect
incubation (upper value) 8 0 no eﬀect
rotation step (yes) 5 1 no eﬀect
type of extraction solvent
methanol/chloroform 1 5 decrease
methanol/
dichloromethane
1 8 no eﬀect
methanol/methyl tert-
butyl ether
20 2 increase
aNumber of lipid species for which the recovery (expressed by
absolute signal intensities) was signiﬁcantly aﬀected (p-value ≤0.05) or
a signiﬁcant change (p-value ≤0.05) in metabolome coverage was
noted.
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overcome hydrophobic as well as polar interactions between
lipids and biopolymers, a balanced solvent ratio between
methanol and methyl tert-butyl ether was optimized during the
subsequent RSM phase, together with other important
quantitative factors (amount of feces, volume of extraction
solvent, and vortex and incubation times).
During RSM modeling, the optimal factor settings were
ascertained on the basis of absolute peak areas of the 53
targeted lipid species only, as diﬀerences in metabolome
coverage were almost not present. Results were visualized by
surface response plots. With respect to the solvent ratio, the
optimum was generally found at a methyl tert-butyl ether/
methanol ratio of 9/1 (v/v). Although this value coincided with
the upper limit of the tested range, the use of pure methyl tert-
butyl ether would not be feasible, as the extraction for some
species belonging to TGL and PL was strongly improved in the
presence of higher amounts of methanol. Therefore, the 9/1
ratio was concluded to be adequate for holistic, class-
representative extraction of lipids. In addition, low volumes of
extraction solvent (5.4 mL) and high amounts of feces (300
mg) were determined to be optimal. However, as instrument
saturation was noted for some lipid species, the amount of feces
was lowered to 200 mg. The ﬁnal volume of solvent for
dissolving the dried extract was also optimized in order to avoid
this kind of saturation as well as to minimize matrix eﬀects by
checking linearity performance (R2) together with metabolome
coverage (both as a function of a dilution series). Despite these
preventive measures, matrix eﬀects can never be excluded
completely.35,36
Method Validation. The methodology was validated for
various criteria, which were evaluated in a targeted and/or
untargeted fashion. Identiﬁcation of compounds was based on
the relative retention time, m/z value of the molecular ion, and
presence of the corresponding 13C isotope.37
Linearity. Targeted evaluation revealed good linearity for the
eight class representatives, as determination coeﬃcients R2 were
all ≥0.9921 (Table 2). Additionally, a dilution series was
established to obtain linearity data for those compounds that
were endogenously present in the fecal material. However, it
should be noted that associated ﬁndings are merely indicative
for the linearity performance, as altered extract dilutions are
accompanied by diﬀerences in matrix density, which may
strongly aﬀect possible matrix ionization eﬀects.31 For the
identiﬁable species (i.e., those that matched one of the 53
compounds that were targeted during method development),
good linearity was concluded for the majority of compounds
(about 90%) (Table S5). Although a higher dilution could be
designated to anticipate biological variation and avoid
saturation in the case of some compounds, reduced
metabolome coverage (at least 2%) would be the case.
Moreover, evaluation of the linearity based on the calibration
curves (with no diﬀerences in matrix density) did not reveal any
saturation eﬀects. Finally, a truly untargeted ﬁve-point linearity
evaluation was performed for the known unknowns (i.e.,
nonidentiﬁed compounds), whereby the established R2 histo-
gram indicated acceptable linearity (R2 ≥ 0.90) for 75.3% of
9126 compounds.
Repeatability. Repeatability was assessed in a targeted
manner by considering the samples from the recovery
experiment, thereby calculating the coeﬃcients of variance for
the eight lipid class representatives and for each fortiﬁcation
level. The method was found repeatable as the average
coeﬃcients of variance were ≤15.6% (Table 2). Repeatability
was also assessed for the endogenously present compounds,
thereby ﬁrst focusing on those lipid species that were
considered during method optimization. As coeﬃcients of
variance were ≤30%,31 good repeatability was concluded for all
compounds (Table S5). Even more, with the exceptions of
valeric acid, anandamide, trimyristin, and tripalmitin, coef-
ﬁcients of variance were ≤16.2%. This ﬁnding was strengthened
by the complete set of detected lipid species, whereby an
acceptable coeﬃcient of variance (i.e., ≤ 30%)31 was retrieved
for 84.5% of 9349 compounds (compounds that were not
present in at least one sample of the considered batch were pre-
excluded).
Reproducibility. On the basis of samples from the recovery
experiment, the within-laboratory reproducibility was also
evaluated in a targeted fashion, focusing on the eight lipid
class representatives. As coeﬃcients of variance were ≤22.4%,
acceptable reproducibility was concluded (Table 2). Addition-
ally, this parameter was evaluated by considering the
compounds that were endogenously present in the fecal
material. When focusing on the lipid species that were targeted
during method optimization, acceptable reproducibility was
concluded, as coeﬃcients of variance were generally ≤30.0%31
(Table S5) with the exception of anandamide and the short-
chain fatty acids propionic acid, butyric acid, and valeric acid.
With respect to the short-chain fatty acids, their relative high
volatility forms a possible explanation, whereby routine
execution of the extraction (as performed by the expert
analyst) seems suﬃcient to warrant reproducible results
(coeﬃcients of variance for repeatability were ≤20.0%).
Table 2. Method Validation Results for Representatives of Eight Lipid Categories
coeﬃcient of variance ± SDa (%)
compd
lipid
class
endogenous
concn
added concn
range linearity
fortiﬁcation
levels recovery ± SD repeatability
within-lab
reproducibility
(ng·mg−1 feces) (ng·mg−1 feces) (R2) (ng·mg−1 feces) (%)
chrysophanol PK 0 0−128 0.9936 25, 50, 100 99.7 ± 12.0 13.6 ± 6.8 22.4 ± 3.3
12-tridecanoic acid FA 0.5 0−64 0.9974 12.5, 25, 50 119.8 ± 4.7 2.8 ± 0.5 11.2 ± 3.5
1-palmitoyl-2-deoyl-sn-glycero-3-
phospho-L-serine
PL 1.2 0−128 0.9945 25, 50, 100 100.8 ± 11.9 5.1 ± 3.7 9.5 ± 3.0
N-oleoyl-D-erythro-sphingosine SP 128.6 0−320 0.9949 25, 50, 100 113.1 ± 2.4 7.0 ± 4.2 8.5 ± 1.7
coenzyme Q10 PR 130.4 0−384 0.9941 50, 100, 200 101.4 ± 5.4 7.0 ± 6.2 8.9 ± 2.50
monoolein GL 357.1 0−1000 0.9985 250, 500, 1000 127.8 ± 10.7 7.2 ± 3.3 10.1 ± 2.0
lactonic sophorolipid SL 0 0−292 0.9921 25, 50, 100 114.2 ± 1.8 15.6 ± 2.8 16.1 ± 2.4
litocholic acid ST 6.1 0−195 0.9936 25, 50, 100 110.0 ± 4.6 7.0 ± 3.7 13.4 ± 3.8
aSD, standard deviation.
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When the complete set of endogenous lipids was considered,
coeﬃcients were ≤30% for 72.6% of 6663 compounds
(compounds that were not present in at least one sample of
the considered batches were pre-excluded).
Instrumental Precision. As a crucial parameter within
metabolomics analyses, instrumental precision was evaluated
in an untargeted manner by considering the repeatability of
three samples analyzed 10 times within a time frame of about
10 h. It was determined that 71.96% of all 8963 compounds
had a coeﬃcient of variance ≤15%. In this regard, to minimize
the impact of instrumental drift on the metabolomics data,
internal quality control samples38 are usually introduced.
Therefore, the repeatability performance was also assessed for
a shorter time span (3 h), corresponding to a sample batch size
that would normally be normalized based on the same internal
quality control samples. As such, 79.31% and 48.28% of all
compounds had a coeﬃcient of variance ≤15% and ≤10%,
respectively. Based on these ﬁndings, a large part of the
variations that were determined for precision (i.e. repeatability
and within-laboratory reproducibility) can be linked to
prevailing instrumental performance.
Recovery. Adequate trueness was concluded for the target
lipid species, as recovery values ranged from 100.8% to 127.8%,
thereby noting a low maximum variation of 12.0% across the
diﬀerent fortiﬁcation levels. This is a fundamental ﬁnding
within the omics context, as untargeted approaches seek for
diﬀerences in metabolite abundance, whereby unstable recovery
could mask these often-subtle diﬀerences.
Detection Capability. As a reﬂection of detection power,
data on the dilution experiment (Table S5) oﬀer a good basis.
Focusing on the targeted approach, out of the 36 endogenously
present compounds (i.e., those that could be detected at the
foreseen dilution), the majority of compounds (30) were still
detectable at the maximum dilution of 1/50, whereas the other
compounds could still be detected at a dilution of at least 1/2.5.
Given the fact that S/N ratios are often inﬁnite, the main
criterion to warrant detection and thus correct compound
identiﬁcation was the presence of the required number of
diagnostic ions in HRMS measurements: that is, the presence
of the monoisotopic peak as well as the 13C isotope ion
(isotope ratio according to CD 2002/657/EC).37
Fecal Lipidomics in a Clinical Context. To demonstrate
the applicability of the validated lipidomics methodology, fecal
samples from individuals without hyperglycemia and from type
2 diabetes patients were analyzed to reveal any health-related
lipidome discrepancies. Fingerprints covered in total 13 153
monoisotopic ions, whereby the majority (70.8%) were
obtained in positive ionization mode. The corresponding data
matrix of ion intensities was subjected to multivariate statistics,
whereby pareto scaling and log transformation were applied to
standardize the range of peak intensities and induce normality,
respectively. Unsupervised principal component analysis (PCA-
X) indicated no outliers (95% Hoteling’s T2 statistics) and
Figure 3. (A) Multivariate analytical workﬂow with PCA-X score plot, (B) OPLS-DA score plot, and (C) heat map with hierarchical clustering to
determine any fecal lipidome discrepancies between control and type 2 diabetes patients.
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suggested acceptable instrument stability during sample
analysis, as internal quality control samples were closely
clustered. The PCA-X score plot (Figure 3A) revealed only
limited clustering according to health state, indicating that
other factors, such as diet, may have a more pronounced impact
on the fecal lipidome. Nevertheless, supervised orthogonal
partial least-squares discriminant analysis (OPLS-DA) (Figure
3B) was able to uncover health-related lipidome discrepancies,
as the corresponding model was compliant with all validation
criteria [i.e., Q2(Y) of 0.728, analysis of variance of cross-
validated residuals (CV-ANOVA) p-value of 1.17 × 10−9, and
good permutation testing]. This implied that a portion (20.4%)
of the fecal lipidome signiﬁcantly (p-value <0.05) diﬀered
according to whether or not type 2 diabetes was present,
enclosing potential to unravel etiological and pathological
pathways in type 2 diabetes and oﬀering new opportunities for
prediction, diagnosis, prognosis, treatment, and management.
In addition, a targeted proﬁling approach was performed,
thereby focusing on the 127 compounds deﬁned in Table S1
and using the retention time, m/z value of the molecular ion,
and 13C isotope pattern of the analytical standards to conﬁrm
the endogenous presence of these compounds in the fecal
material of the participants. As such, 54 out of 127 compounds
were found to be frequently present in fecal material (Figure
3C). Some other compounds (n = 13) were only sporadically
present across participants (prevalence <50% within a study
cohort; not shown in Figure 3C). However, by use of the
relative levels of these metabolites, full discrimination of the
study groups was not achieved on the basis of hierarchical
clustering (one minus Pearson correlation, Morpheus online
software). This ﬁnding points toward the added value of true
holistic untargeted lipidomic ﬁngerprinting compared to
targeted analytical strategies.
■ CONCLUSIONS
On the basis of the fact that lipids have been associated with
various biological functions, the domain of lipidomics has
emerged as a valuable complement of polar metabolomics.
However, a validated method that covers the analysis of all
eight lipid categories was missing for feces. Indeed, in recent
years, feces has surfaced as an essential matrix for in-depth
metabolomics studies because of its unique link to the gut
microbiome and the interaction with diet. This shortcoming
was tackled by the present work, establishing a lipidomics
methodology with good analytical performance in terms of
linearity and repeatability for a high percentage (i.e., about
75%) of about 9000 endogenous fecal compounds under
consideration. Besides, as the analytical performance for all lipid
categories was taken into account during both method
development and validation, holistic coverage was warranted.
Moreover, the possibility to fragment quadrupole-selected
metabolites by the hybrid quadrupole Q-Exactive Orbitrap
platform may aid in identiﬁcation of unknowns, which is
acknowledged as the major bottleneck in metabolomics. In this
regard, the acquired LC elution proﬁle oﬀers potential for
retention time prediction, thus also providing valuable input for
the identiﬁcation process. Eventually, analysis of fecal samples
from euglycemic individuals and patients with type 2 diabetes
revealed that our method was capable of detecting 13 153
monoisotopic ions and allowed diﬀerentiation according to
glycemic state. These ﬁndings indicate the method’s high
lipidome coverage and robust semiquantitation of lipid
concentration levels. As such, this lipidomics method is
considered highly suited for holistic ﬁngerprinting of the gut
phenotype, which may open the door toward advanced
progress in clinical and nutritional research.
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